122 related articles for article (PubMed ID: 18533260)
41. Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases.
Terré C; Nguyen-Khac F; Barin C; Mozziconacci MJ; Eclache V; Léonard C; Chapiro E; Farhat H; Bouyon A; Rousselot P; Choquet S; Spentchian M; Dubreuil P; Leblond V; Castaigne S
Leukemia; 2006 Sep; 20(9):1634-6. PubMed ID: 16838026
[No Abstract] [Full Text] [Related]
42. [Establishment of immortalized B-lymphoblastoid cell lines of keloid pedigree and its karyotype analysis].
Song M; Gao JH; Yan X; Liu XJ; Chen Y
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1760-2. PubMed ID: 17259115
[TBL] [Abstract][Full Text] [Related]
43. High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.
Braggio E; Keats JJ; Leleu X; Wier SV; Jimenez-Zepeda VH; Schop RF; Chesi M; Barrett M; Stewart AK; Dogan A; Bergsagel PL; Ghobrial IM; Fonseca R
Clin Lymphoma Myeloma; 2009 Mar; 9(1):39-42. PubMed ID: 19362969
[TBL] [Abstract][Full Text] [Related]
44. [Waldenström's syndrome and chromosome aberrations].
Catena R; Gaspari G
Quad Sclavo Diagn; 1975 Dec; 11(4):794-806. PubMed ID: 822472
[TBL] [Abstract][Full Text] [Related]
45. Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia.
Henry T; Fonseca R
Curr Opin Hematol; 2007 Jul; 14(4):369-74. PubMed ID: 17534163
[TBL] [Abstract][Full Text] [Related]
46. [Molecular basis of Waldenström macroglobulinemia].
Sevčíková S; Novák L; Kubiczková L; Dementyeva E; Ríhová L; Hájek R
Klin Onkol; 2012; 25(6):413-20. PubMed ID: 23301642
[TBL] [Abstract][Full Text] [Related]
47. Genetic factors and pathogenesis of Waldenström's macroglobulinemia.
Monge J; Braggio E; Ansell SM
Curr Oncol Rep; 2013 Oct; 15(5):450-6. PubMed ID: 23901022
[TBL] [Abstract][Full Text] [Related]
48. Histological characteristics of 21 Papua New Guinean children with high-grade B-cell lymphoma, which is frequently associated with EBV infection.
Nomura Y; Lavu EK; Muta K; Niino D; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
Pathol Int; 2008 Nov; 58(11):695-700. PubMed ID: 18844934
[TBL] [Abstract][Full Text] [Related]
49. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A
Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249
[TBL] [Abstract][Full Text] [Related]
50. [Chromosomal abnormalities and Waldenström macroglobulinemia].
Berger R; Nguyen-Khac F
Pathol Biol (Paris); 2008 Sep; 56(6):400-6. PubMed ID: 18456427
[TBL] [Abstract][Full Text] [Related]
51. Indolent lymphomas other than follicular and marginal zone lymphomas.
Peinert S; Seymour JF
Hematol Oncol Clin North Am; 2008 Oct; 22(5):903-40, viii. PubMed ID: 18954743
[TBL] [Abstract][Full Text] [Related]
52. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
Leleu X; Hunter ZR; Xu L; Roccaro AM; Moreau AS; Santos DD; Hatjiharissi E; Bakthavachalam V; Adamia S; Ho AW; Soumerai J; Patterson CJ; Manning RJ; Hamilton S; Verselis S; Fox E; Carrasco R; Ghobrial IM; Treon SP
Br J Haematol; 2009 Apr; 145(1):59-63. PubMed ID: 19220283
[TBL] [Abstract][Full Text] [Related]
53. [Chromosome studies in Waldenström's disease].
Ganner E
Wien Klin Wochenschr; 1967 Jan; 79(1):20-1. PubMed ID: 4962035
[No Abstract] [Full Text] [Related]
54. [The genetic nature of Waldenstrom's macroglobulinemia].
Bottura C
Prensa Med Argent; 1966; 53(1):223-4. PubMed ID: 4964733
[No Abstract] [Full Text] [Related]
55. [Pathologic anatomy and cytology of Waldenström's disease].
Veyret V; Langlois J
J Med Bord; 1967 Sep; 144(9):1267-71. PubMed ID: 4988701
[No Abstract] [Full Text] [Related]
56. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia.
Issa GC; Leblebjian H; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2011 Jul; 18(4):260-5. PubMed ID: 21519243
[TBL] [Abstract][Full Text] [Related]
57. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
58. Phenotypic evolution of Waldenstrom's macroglobulinemia to extramedullary plasmacytoma.
Bashir Q; Lee CK; Stuart RW; Smith ML; Ryder J; Gonzalez R
J Clin Oncol; 2008 May; 26(14):2408-10. PubMed ID: 18467735
[No Abstract] [Full Text] [Related]
59. Establishment and characterization of a new human acute myelocytic leukemia cell line SH-2 with a loss of Y chromosome, a derivative chromosome 16 resulting from an unbalanced translocation between chromosomes 16 and 17, monosomy 17, trisomy 19, and p53 alteration.
Qiu H; Xue Y; Zhang J; Pan J; Dai H; Wu Y; Wang Y; Chen S; Wu D
Exp Hematol; 2008 Nov; 36(11):1487-95. PubMed ID: 18715689
[TBL] [Abstract][Full Text] [Related]
60. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
Ise M; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
